Missouri Supreme Court ruling could help J&J in talc cases
February 25, 2019Sales and Marketing Cancer, J&J, JJ, asbestos, baby powder, lawsuits, legal, talc
The Missouri Supreme Court has ruled that the practice of combining two or more cases in order to allow courts …
Roche set to acquire Spark Therapeutics in $4.8 billion deal
February 25, 2019Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma
Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …
Iran ready to export medicines to Venezuela
February 25, 2019Sales and Marketing FDA, Iran, Venezuela, biotech, global, pharma
The chairman of the Iranian Food and Drug Administration (FDA) Mehdi Pirsalehi, has said that Iran is ready to export …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
US Department of Justice investigate J&J over Baby Powder allegations
February 22, 2019Medical Communications Cancer, J&J, JJ, Johnson and Johnson, USA, asbestos, oncology, talc
The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that Johnson’s …
MHRA warns of congenital malformation risk of neo-mercazole during pregnancy
February 22, 2019Medical Communications, Research and Development MHRA, neo-mercazole, pharma
UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) …
Genetically modified twins may have been altered in a way that improves memory and cognition
February 22, 2019Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing
The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …
Poison control calls for kratom increase from one a month to two a day, study shows
February 22, 2019Medical Communications USA, herbal medicines, kratom, poison control, toxicology
The number of phone calls to US poison control centres over exposures to kratom – an herbal drug with opioid …
FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths
February 21, 2019Research and Development Cancer, FDA, Xencor, leukaemia, pharma
Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …
Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market
February 21, 2019Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior
Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …
Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death
February 21, 2019Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis
Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …
Teva settles ‘pay-to-delay’ case with FTC
February 21, 2019Business Services, Sales and Marketing FTC, Teva, antitrust, drugs, generics, monopoly
Teva Pharmaceuticals has settled a dispute with the Federal Trade Commission (FTC) over three separate federal court antitrust lawsuits involving …
Avara Avlon falls into administration putting 270 Bristol jobs at risk
February 21, 2019Manufacturing and Production AstraZeneca, Avara Avlon, Bristol, CDMO, Jobs, UK, manufacturing
Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at …
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
FDA approves Indian firm Alembic’s generic of Teva’s Diamox
February 20, 2019Research and Development ANDA, Alembic, Gujurat, US FDA, diamox, generics
The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, …
Pfizer and Eli Lilly’s chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial
February 20, 2019Research and Development
US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 …
Poland and Slovenia included in US-EU mutual recognition agreement
February 20, 2019Research and Development EU, GMP, Poland, Slovenia, USA, mutual recognition
Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
Philippines’ FDA halts sales of Sanofi’s dengue vaccine
February 19, 2019Manufacturing and Production, Sales and Marketing Philippines, Sanofi, dengue, dengvaxia, pharma
The marketing authorisation for Sanofi’s dengue vaccine Dengvaxia has been revoked in the Philippines after the country’s Food and Drug …
San Francisco scientists use CRISPR to develop stem cells invisible to the immune system
February 19, 2019Manufacturing and Production Nature Biotechnology, Stem cells, UC San Francisco, iPSCs, regenerative medicine
Scientists at UC San Francisco have used the gene editing tool CRISPR Cas9 to manufacture pluripotent stem cells (stem cells …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
